Search Results - "HABA, J"

Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study by Heinzer, R, Dr, Vat, S, MD, Marques-Vidal, P, MD, Marti-Soler, H, PhD, Andries, D, RPSGT, Tobback, N, RPSGT, Mooser, V, MD, Preisig, M, MD, Malhotra, A, MD, Waeber, G, MD, Vollenweider, P, MD, Tafti, M, PhD, Haba-Rubio, J, MD

“…Summary Background Sleep-disordered breathing is associated with major morbidity and mortality. However, its prevalence has mainly been selectively studied in…”
Get full text

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study by Alba, E., Calvo, L., Albanell, J., De la Haba, J.R., Arcusa Lanza, A., Chacon, J.I., Sanchez-Rovira, P., Plazaola, A., Lopez Garcia-Asenjo, J.A., Bermejo, B., Carrasco, E., Lluch, A.

“…Luminal breast cancer is a highly endocrine responsive disease. However, the therapeutic benefit of chemotherapy (CT) in this population is not fully…”
Get full text

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial by Bianchini, G., Pusztai, L., Pienkowski, T., Im, Y.-H., Bianchi, G.V., Tseng, L.-M., Liu, M.-C., Lluch, A., Galeota, E., Magazzù, D., de la Haba-Rodríguez, J., Oh, D.-Y., Poirier, B., Pedrini, J.L., Semiglazov, V., Valagussa, P., Gianni, L.

“…To investigate in the NeoSphere trial the contribution of the immune system to pathologic complete response in the breast (pCRB) after neoadjuvant docetaxel…”
Get full text

Nitric oxide and cancer: the emerging role of S-nitrosylation by Aranda, E, López-Pedrera, C, De La Haba-Rodriguez, J R, Rodriguez-Ariza, A

“…Nitric oxide (NO˙) is a short-lived, endogenously produced gas that is highly diffusible across cell membranes and acts as a signaling molecule in the body…”
Get more information

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials by Martín, M., Loibl, S., Hyslop, T., De la Haba-Rodríguez, J., Aktas, B., Cirrincione, C.T., Mehta, K., Barry, W.T., Morales, S., Carey, L.A., Garcia-Saenz, J.A., Partridge, A., Martinez-Jañez, N., Hahn, O., Winer, E., Guerrero-Zotano, A., Hudis, C., Casas, M., Rodriguez-Martin, C., Furlanetto, J., Carrasco, E., Dickler, M.N.

“…Randomised trials comparing the efficacy of standard endocrine therapy (ET) versus experimental ET + bevacizumab (Bev) in 1st line hormone…”
Get full text

Gestational breast cancer: distinctive molecular and clinico-epidemiological features by de la Haba-Rodríguez, J. R., Mínguez, P., Rojo, F., Martín, M., Alba, E., Servitja, S., Prat, A., Pérez-Fidalgo, J. A., Gavilá, J., Morales, C., Rodriguez-Lescure, A., Herrero, C., Peña-Enriquez, R, Herranz, J., Hernando, C., Hernández-Blanquisett, A., Guil-Luna, S., Martinez, MT, Blanch, S., Caballero, R., Martín, N., Pollán, M., Guerrero-Zotano, A., Bermejo, B.

“…Gestational breast cancer (GBC), defined as breast cancer (BC) diagnosed during pregnancy or the first-year post-partum, accounts for 6–15% of BC cases in…”
Get full text

A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy by Polley, Mei-Yin C., Dickler, Maura N., Sinnwell, Jason, Tenner, Kathleen, de la Haba, Juan, Loibl, Sibylle, Goetz, Matthew P., Bergh, Jonas, Roberston, John, Couch, Fergus, Ellis, Matthew J., Martin, Miguel

“…Purpose Endocrine therapy (ET) is an effective strategy to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−)…”
Get full text

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial by Alba, E, Albanell, J, de la Haba, J, Barnadas, A, Calvo, L, Sánchez-Rovira, P, Ramos, M, Rojo, F, Burgués, O, Carrasco, E, Caballero, R, Porras, I, Tibau, A, Cámara, M C, Lluch, A

“…Background: The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients…”
Get full text

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain by Lopez-Vivanco, G., Salvador, J., Diez, R., López, D., De Salas-Cansado, M., Navarro, B., De la Haba-Rodríguez, J.

“…Purpose To describe healthcare professional (HCP) and patient time and related costs associated with trastuzumab intravenous infusion (IV) and trastuzumab…”
Get full text

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study by Ruíz-Borrego, Manuel, Guerrero-Zotano, Angel, Bermejo, Begoña, Ramos, Manuel, Cruz, Josefina, Baena-Cañada, Jose Manuel, Cirauqui, Beatriz, Rodríguez-Lescure, Álvaro, Alba, Emilio, Martínez-Jáñez, Noelia, Muñoz, Montserrat, Antolín, Silvia, Álvarez, Isabel, Del Barco, Sonia, Sevillano, Elena, Chacón, José Ignacio, Antón, Antonio, Escudero, María José, Ruiz, Victoria, Carrasco, Eva, Martín, Miguel

“…Purpose GEICAM/2006–10 compared anastrozole (A) versus fulvestrant plus anastrozole (A + F) to test the hypothesis of whether a complete oestrogen blockade is…”
Get full text

Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study by Guerrero-Zotano, Á., Pérez-García, J.M., Ruiz-Borrego, M., Bermejo, B., Gil-Gil, M., de la Haba, J., Alba Conejo, E., Quiroga, V., Carañana, V., Urruticoechea, A., Morales, S., Bellet, M., Antón, A., Fernández-Abad, M., Sánchez-Rovira, P., Calabuig, L., Pérez-Escuredo, J., Sampayo-Cordero, M., Cortés, J., Llombart-Cussac, A.

“…The effect of the addition of cyclin-dependent kinases 4 and 6 inhibitors to endocrine therapy in terms of molecular downstaging remains undetermined…”
Get full text

Electronic health records and patient registries in medical oncology departments in Spain by Ribelles, N., Alvarez-Lopez, I., Arcusa, A., Chacon, J. I., de la Haba, J., García-Corbacho, J., Garcia-Mata, J., Jara, C., Jerez, J. M., Lázaro-Quintela, M., Leon-Mateos, L., Ramirez-Merino, N., Tibau, A., Garcia-Palomo, A.

“…Purpose We aimed to evaluate the current situation of electronic health records (EHRs) and patient registries in the oncology departments of hospitals in…”
Get full text

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial by Vaz Batista, M., Pérez-García, J.M., Cortez, P., Garrigós, L., Fernández-Abad, M., Gion, M., Martínez-Bueno, A., Saavedra, C., Teruel, I., Fernandez-Ortega, A., Servitja, S., Ruiz-Borrego, M., de la Haba-Rodríguez, J., Martrat, G., Pérez-Escuredo, J., Alcalá-López, D., Sampayo-Cordero, M., Braga, S., Cortés, J., Llombart-Cussac, A.

“…Trastuzumab deruxtecan (T-DXd) is approved for human epidermal growth factor receptor 2 (HER2)-positive and HER2-low advanced breast cancer (ABC). T-DXd has…”
Get full text

Splenic sarcoidosis: a case report and review of the imaging findings of multiple incidental splenic lesions as the initial presentation of sarcoidosis by Raber, Earl L, Haba, J, Beck, Paul

“…MRI is helpful in characterizing splenic lesions, but there can be significant variability and overlap in the appearance of both benign and malignant splenic…”
Get full text

A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study by Gavilá, J., De La Haba, J., Bermejo, B., Rodríguez-Lescure, Á., Antón, A., Ciruelos, E., Brunet, J., Muñoz-Couselo, E., Santisteban, M., Rodríguez Sánchez, C. A., Santaballa, A., Sánchez Rovira, P., García Sáenz, J. Á., Ruiz-Borrego, M., Guerrero-Zotano, A. L., Huerta, M., Cotes-Sanchís, A., Lao Romera, J., Aguirre, E., Cortés, J., Llombart-Cussac, A.

“…Purpose To evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients…”
Get full text

1882 CASCADE study: Epidemiological analysis of current natural history and treatment patterns of metastatic breast cancer in spain by Martínez Dueñas, E, Zamora, P, Servitja, S, Santaballa, A, García Mata, J, De Paz, L, Plata, Y, Garau, I, Florian, J, Chacón, J.I, De la Haba, J, García, P, San José, B, Riva, F, Rodríguez-Villanueva, J, Seguí, M.A

Get full text

Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial by Del Barco, S, Colomer, R, Calvo, L, Tusquets, I, Adrover, E, Sánchez, P, Rifà, J, De la Haba, J, Virizuela, J. A

“…Doxorubicin and gemcitabine are active as single agents in breast cancer, have different mechanisms of action, and mainly have non-overlapping side effects…”
Get full text

R&D status of 64-channel photon-counting imaging module by Kawai, Y., Haba, J., Suyama, M.

“…A high speed photon-counting imaging module that utilizes the previously developed GaAsP-photocathode 64-channel Hybrid Photo-Detector (HPD) has been…”
Get full text

High Speed HPD for Photon Counting by Fukasawa, A., Haba, J., Kageyama, A., Nakazawa, H., Suyama, M.

“…We have succeeded in the development of a high-speed Hybrid Photodetector (HPD), by using a reduced electron lens and a newly developed avalanche diode (AD)…”
Get full text

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer by Salvador, J., Manso, L., de la Haba, J., Jaen, A., Ciruelos, E., de Villena, M. C., Gil, M., Murias, A., Galan, A., Jara, C., Bayo, J., Baena, J. M., Casal, J., Mel, J. R., Blancas, I., Sanchez Rvira, P.

“…Background Efficacy and safety data for combining bevacizumab, gemcitabine, and paclitaxel for locally advanced/metastatic breast cancer are limited. Patients…”
Get full text